Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Hits QuantWave's Price Target Forecast with 20.07% Profit

August 08, 2023
QuantWave, the automated forecasting platform, recently saw one of its predictions for ELI LILLY AND COMPANY come to fruition, achieving a significant 20.07% profit. The forecast signal was initiated on May 12, 2023, when the stock was trading at $428.28, with a predicted long direction. On August 8, 2023, the stock reached the forecasted target price of $514.21, validating QuantWave's accuracy in predicting market movements.

Several factors may have contributed to ELI LILLY AND COMPANY's positive performance. With a strong pipeline of pharmaceutical products and a track record of innovation in the healthcare sector, the company has positioned itself for growth. Market conditions, including industry trends and macroeconomic factors, may have also played a role in driving the stock price higher.

QuantWave's success in forecasting ELI LILLY AND COMPANY's price target demonstrates the platform's effectiveness in providing valuable insights for investors. By leveraging QuantWave's analytics, users can access predictions for a wide range of stocks, opening up opportunities for potential profits in the financial markets. For those interested in refining their investment strategy, QuantSchool offers educational resources on how to maximize returns using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

PFEDecember 14, 2022PFIZER INC. Hits Price Target Forecast with 9.65% Profit: A Success Story for QuantWave  ~1 min.

In a significant milestone for QuantWave, the automated forecasting platform successfully predicted a long signal for PFIZER INC. on August 12, 2022, when the stock was trading at 43.24 $....

REGNFebruary 9, 2025Regeneron Pharmaceuticals Inc REGN Reports Strong Earnings in Q4 2024  ~2 min.

Regeneron Pharmaceuticals Inc., a leading biotechnology company, announced its impressive financial results for the fourth quarter of 2024....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 34.08% Profit: A Success Story for QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) recently achieved a price target forecast set by QuantWave, resulting in a remarkable profit of 34.08% for investors....

REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....